

17th October, 2017

Innovation in support of life

The Manager, Listing Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Fax No.:022-26598237 / 38 NSE Symbol: PANACEABIO BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Fax No.:022–22721919, 3121 BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec receives certificate of GMP Compliance with manufacturing authorizations for 22 medicinal products from State Service of Ukraine on Medicines and Drugs Control

Dear Sir,

The Company is pleased to announce that it has received the Certificate of GMP Compliance from State Service of Ukraine on Medicines and Drugs Control with manufacturing authorization for 22 medicinal products, including 4 oncology products valid till June 24, 2020. Under this Manufacturing Authorization, the Company's oral solid dosage manufacturing facility and oncology facility at Baddi, Himachal Pradesh have been certified as complying with the Good Manufacturing Practices.

A copy of the Press Release titled "Panacea Biotec receives certificate of GMP Compliance with manufacturing authorizations for 22 medicinal products from State Services of Ukraine on Medicines and Drug Control" being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you, Sincerely yours, for **Panacea Biotec Ltd.**

Vinod Goel

Group CFO and Head Legal & Company Secretary

Encl. : As above.

B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoe@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070





Innovation in support of life

Panacea Biotec receives Certificate of GMP Compliance with manufacturing authorizations for 22 medicinal products from State Service of Ukraine on Medicines and Drugs Control

New Delhi - October 17, 2017:

Panacea Biotec, one of India's highly progressive research based biotechnology Company, announces that it has received the Certificate of GMP Compliance from State Service of Ukraine on Medicines and Drugs Control with Manufacturing Authorization for 22 medicinal products, including 4 oncology products for a period valid till June 24, 2020. Under this Manufacturing Authorization the Company's oral solid dosage manufacturing facility and oncology facility at Baddi, Himachal Pradesh have been certified as complying with the Good Manufacturing Practices. Ukraine is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) which has 49 countries from all over the world including Europe, Africa, America, Asia and Australasia. With this approval, registration of these 22 products can now be undertaken in the 49 PIC/S countries on a fast track basis as PIC/S brings about single window GMP Certification facilitation with provision to reduce duplication of inspections and enhance market access of the medicinal products amongst all member nations.

The 22 products under approval are in various therapeutic categories including organ transplantation, diabetes management, oncology, piles management, pain management and gastroenterology etc. Both the oral solid dosage manufacturing facility and oncology facility were inspected by the auditors from State Services of Ukraine on Medicines and Drug Control during the period from 19.06.2017 to 24.06.2017.

Speaking on the occasion Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Ltd said "the Certificate of GMP Compliance received from Ukrainian Authorities strengthens and opens 49 countries for Company's 22 products which can be registered in an expeditious manner under the PIC/s mechanism."

About Panacea Biotec

Panacea Biotec Limited is a leading research based biotechnology Company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and Biotechnology Companies in India. The Company is also amongst the top 15 pharmaceutical companies (AIOCD AWACS-MAT MAR-2017) in its represented market India

Panacea Biotec Ltd.

B-1 Extn. / A-27 Mohan Co-operative Industrial Estate, Mathura Road New Delhi -110 044 Ph.: +91-11-41678000/ 9000, Fax: +91-11-26940621,

> Email: rajeshjain@panaceabiotec.com CIN: L33117PB1984PLC022350

and amongst top 60 pharmaceutical Companies in India. The Company has been awarded with the prestigious "India Innovation Award 2016 – Top 50" by Clarivate Analytics.

The product portfolio of includes highly innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric vaccines. It is working on a robust pipeline of high barrier to entry generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastroretentive systems.

It has introduced its products in around 30 countries across the world, including USA, Germany and Russian Federation, through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations.

The company's state-of-the-art manufacturing facilities for vaccines and pharmaceutical formulations comply with several leading regulatory agencies worldwide. The company has around 2,500 employees including around 100 scientists working across 4 R&D centers of the Company.

For more information, please contact -

Mr. P. D. Karan

Vice President - Corporate Communication & Business Development

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi - 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com
Web: www.panaceabiotec.com